Get the Stockscreener App
0.00
100.00%
-76.01
After Hours:
76.04
76.04
+
Hologic Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$76.01
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$16.97B
Revenue:
$4.13B
Net Income/Loss:
$543.90M
P/E Ratio:
0.00
EPS:
2.41
Net Cash Flow:
$957.20M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$76.07
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
0.00 | 16.97B | 4.13B | 543.90M | 957.20M | 2.41 |
ISRG
Intuitive Surgical Inc
|
403.18 | 144.07B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
143.92 | 39.67B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.12 | 31.54B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.30 | 30.39B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
191.26 | 27.36B | 5.54B | 1.52B | 1.74B | 10.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Downgrade | Argus | Buy → Hold |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-21-25 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic marks 40 years with new sustainability report, shares on NASDAQ in focus - AD HOC NEWS
The Panther Fusion SARS-CoV-2 Assay from Hologic Inc.fully automated PCR for high-throughput labs - AD HOC NEWS
Hologic Inc (HOLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Needles used to detect breast cancer in shortage from recall - MSN
Subtle hardware, big impactHologic Brevera in everyday breast biopsy - AD HOC NEWS
Hologic Stockweekly sector review and peer comparison - AD HOC NEWS
Quietly powerful in the lab, Hologic’s Aptima HPV assay pushes cervical screening forward - AD HOC NEWS
Le nouveau Rapport de durabilité d’Hologic célèbre 40 ans de réalisations - Eagle-Tribune
Hologic Inc (HOLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
How hospitals are managing Medline, Hologic product shortages - Modern Healthcare
Twin Securities, Inc.'s Hologic Inc(HOLX) Holding History - GuruFocus
Monongahela All Cap Value Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Hologic Inc (HOLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Hologic Inc (HOLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Hologic Inc (HOLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Hologic Inc (HOLX) Institutional Confidence - TradingKey
Hologic’s New Sustainability Report Marks 40 Years of Impact - Hologic
Needles Used to Detect Breast Cancer in Shortage From Recall - Bloomberg
Hologic wins patent case against Siemens Healthineers over mammo technology - DOTmed
Needles Used to Detect Breast Cancer in Shortage After Recall - Bloomberg.com
Hologic Inc (HOLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FDA warns breast biopsy needle shortage to continue into 2027 - MedTech Dive
Hologic Inc (HOLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Hologic Wins Patent Battle Against Siemens Healthineers, Orders Mammography System Recall - Medical Product Outsourcing
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology - TradingView
Quality Beyond Compliance: Malik Khan on Protecting Patients and Powering Performance - Hologic
Hologic Stock (US4364401012): Valuation and women's health strategy in focus after S&P 500 exit - AD HOC NEWS
Hologic Inc Stock (US4364401012): S&P 500 exit keeps women’s health specialist on U.S. investors� - AD HOC NEWS
Yakira Capital Management, Inc.'s Hologic Inc(HOLX) Holding History - GuruFocus
Hologic Stock (US4364401012): S&P 500 exit puts women’s health specialist back under the microscop - AD HOC NEWS
Hologic Stock (US4364401012): Valuation Metrics Under the Microscope - AD HOC NEWS
Siemens Hit With UPC Sales Ban Over Breast-Screening Tech - Law360
First Trust Merger Arbitrage Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Siemens ordered to recall mammography device across European countries - Life Sciences Intellectual Property Review
Life After Breast Cancer: Why Treatment Decisions Are Becoming More Personal - Hologic
· Analyst Forecast - MLQ.ai
T-Score & DXA: How Hologic Helped Define Bone Health - Hologic
LivaNova Appoints Anne Liddy as Chief Legal Officer - Business Wire
Hologic CEO Steve MacMillan to retire as go-private deal closes - Investing.com
BlackRock Event Driven Equity Fund's Hologic Inc(HOLX) Holding History - GuruFocus
Newly Published Data Suggests AI’s Potential to Help Streamline Mammography Reviews While Maintaining High Effectiveness in Finding Cancer - Hologic
GABELLI & Co INVESTMENT ADVISERS, INC.'s Hologic Inc(HOLX) Holding History - GuruFocus
Hologic, Inc. (HOLX) Stock Analysis: Navigating Modest Growth And Strategic Stability - DirectorsTalk Interviews
Hologic's BCI test shows growing impact in endocrine therapy decisions - MSN
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions - BioSpace
Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index - Business Wire
Hologic, Inc. (HOLX) Stock Analysis: Navigating Steady Growth In The Healthcare Sector - DirectorsTalk Interviews
OCONNOR, A Distinct Business Unit Of UBS ASSET MANAGEMENT AMERICAS (LLC) HOLX Holdings History - GuruFocus
Absolute Gestao de Investimentos Ltda.'s Hologic Inc(HOLX) Holding History - GuruFocus
The Official Home of the Women's Tennis Association | WTA Tennis - WTA Tennis
Hologic, Inc. (HOLX) Stock Analysis: Steady Growth With A Strong Focus On Women's Health - DirectorsTalk Interviews
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):